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Introduction: Basal-like and luminal breast cancers have distinct stromal–epithelial interactions, which play a role in
progression to invasive cancer. However, little is known about how stromal–epithelial interactions evolve in benign
and pre-invasive lesions.
Methods: To study epithelial–stromal interactions in basal-like breast cancer progression, we cocultured reduction
mammoplasty fibroblasts with the isogenic MCF10 series of cell lines (representing benign/normal, atypical
hyperplasia, and ductal carcinoma in situ). We used gene expression microarrays to identify pathways induced by
coculture in premalignant cells (MCF10DCIS) compared with normal and benign cells (MCF10A and MCF10AT1).
Relevant pathways were then evaluated in vivo for associations with basal-like subtype and were targeted in vitro to
evaluate effects on morphogenesis.
Results: Our results show that premalignant MCF10DCIS cells express characteristic gene expression patterns of
invasive basal-like microenvironments. Furthermore, while hepatocyte growth factor (HGF) secretion is upregulated
(relative to normal, MCF10A levels) when fibroblasts are cocultured with either atypical (MCF10AT1) or premalignant
(MCF10DCIS) cells, only MCF10DCIS cells upregulated the HGF receptor MET. In three-dimensional cultures,
upregulation of HGF/MET in MCF10DCIS cells induced morphological changes suggestive of invasive potential, and
these changes were reversed by antibody-based blocking of HGF signaling. These results are relevant to in vivo
progression because high expression of a novel MCF10DCIS-derived HGF signature was correlated with the basal-
like subtype, with approximately 86% of basal-like cancers highly expressing the HGF signature, and because high
expression of HGF signature was associated with poor survival.
Conclusions: Coordinated and complementary changes in HGF/MET expression occur in epithelium and stroma
during progression of pre-invasive basal-like lesions. These results suggest that targeting stroma-derived HGF
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Normal development and homeostasis requires epithe-
lial–stromal interactions. Cancers must evolve and adapt
in stromal context, and therefore cancer progression de-
pends on an initiated cell’s ability to utilize permissive
signals and circumvent repressive signals [1]. Under evo-
lutionary theories of cancer, tumors that progress have
characteristics that are advantageous given their micro-
environments [2]. Cancer cells may also modify their en-
vironments to induce growth-promoting signals. Recent
data suggest that host and/or stromal factors affect the
tumor subtype. For example, aging stroma may influence
which tumor subtypes develop or may promote more
aggressive disease [3,4]. Conversely, tumor characteris-
tics may define epithelium–stromal interactions. Basal-
like breast cancers have a distinct microenvironment
interaction pattern relative to other breast cancer sub-
types [5] and appear to be associated with distinct im-
mune microenvironments [6-8]. These and many other
data suggest that complementary epithelial–stromal co-
evolution is influential in cancer development. However,
since most of these studies have examined epithelial–
stroma interactions after tumors have acquired invasive
characteristics, it is not well known how host–tumor in-
teractions are maintained earlier in disease progression.
We hypothesized that basal-like breast cancers may
have unique interactions with their microenvironments
beginning in the early stages of progression. In epidemi-
ologic studies, there is evidence that basal-like breast
cancers progress very rapidly through the ductal carcin-
oma in situ (DCIS) stage compared with other cancers
[9]. However, many of the DCIS-adjacent stromal tissue
studies have been from patients who also have invasive
cancers in the same breast [10], and given the cross-
sectional nature of these studies (with data at only a single
time point in the progression of disease) it is difficult to
identify epithelial–stromal interactions that are induced
during progression. In addition, stroma from DCIS le-
sions and invasive tumors are very similar, suggesting
that stromal changes may occur prior to invasion
[10,11]. It is important to identify pathways that are
altered in the stroma prior to invasion as these pathways
may be targetable.
To study epithelial–stromal interactions in the pre-inva-
sive phases of basal-like breast cancer development, we
employed the MCF10 cell line series in cocultures. The
MCF10 cell lines represent an isogenic background (being
derived from a single patient), but express pathologic
characteristics in xenografts, ranging from non-neoplastic
benign morphology (MCF10A) to atypical hyperplasia
(MCF10AT1) to DCIS (MCF10DCIS). These lines were
cocultured with fibroblasts (both two-dimensional on
plastic and three-dimensional (3D) in Matrigel®/collagen).
Cell-based assays and gene expression profiling wereconducted to track the evolution of cell–cell interactions
with progression. The resulting experimental data, to-
gether with patient data, suggest an important role for
hepatocyte growth factor (HGF) signaling in premalignant
to invasive basal-like breast cancer.
Methods
Cell lines and treatments
MCF10A, MCF10AT1 and MCF10DCIS.com (referred to
as MCF10DCIS) were purchased from Karmanos Cancer
Institute (Detroit, MI, USA) and Asterand (Detroit, MI,
USA). These cell lines were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 5% horse
serum, 50 units/ml penicillin, and 50 units/ml strepto-
mycin, 5 μg/ml insulin (GIBCO, Life Technologies, Carls-
bad, CA, USA), 1 μg/ml hydrocortisone (Sigma-Aldrich,
St. Louis, MO, USA), cholera toxin (EMD Millipore,
Darmstadt, Germany) and Epidermal Growth Factor
(Invitrogen, Life Technologies). Cocultures were also
performed in this media after ascertaining that reduction
mammoplasty fibroblasts (RMFs) maintained their RPMI
1640 doubling times in this Dulbecco’s modified Eagle’s
medium/F12.
MCF7 cells (luminal cell line) and SUM149 cells (basal-
like cell line) were purchased from ATCC (Manassas, VA,
USA). RMFs (htert-immortalized fibroblasts from reduc-
tion mammoplasty [12]) were provided by Dr Charlotte
Kupperwasser (Tufts University, Medford, MA, USA).
Similar to previous studies [13], we selected an htert-
immortalized fibroblast cell line over primary cell lines for
several reasons. Primary cells have a limited lifespan; after
nine passages they senesce, allowing insufficient time to
perform many assays (such as the 3D assays described
below). Even prior to senescence, the aging process and
patient-to-patient variation affects gene expression, as
shown by quantitative reverse transcription PCR in
Additional file 1. Primary fibroblasts were obtained from
breast tissue of patients undergoing breast surgery for pri-
mary invasive breast carcinoma at UNC Hospitals. Tissue
specimens were procured under an Institutional Review
Board-approved protocol by the Lineberger Cancer Center
Tissue Procurement Facility. The isolation protocol of
these cancer- adjacent normal-associated fibroblasts and
cancer-associated fibroblasts was described previously
[13]. For this panel of 14 primary cancer-normal associ-
ated fibroblasts (obtained from histologically normal tis-
sue adjacent to a tumor) and cancer-associated fibroblasts
at different passages, HGF levels vary by more than 500-
fold. These cell lines were maintained at 37°C and 5%
CO2 in RPMI 1640 or Dulbecco’s modified Eagle’s
medium/F12 with L-glutamine (GIBCO) supplemented
with 10% fetal bovine serum (Sigma-Aldrich) and 50
units/ml penicillin and 50 units/ml streptomycin (GIBCO)
as described elsewhere [5,13]. All cell lines were tested for
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Coculture conditions and treatments
Two types of cocultures were performed using media and
culture conditions described above and previously [5].
Direct cocultures are defined as a coculture where the two
cell types are grown in direct physical contact, in the same
well. The epithelial:RMF ratios plated for these cocultures
were 1:4, 1:2, 1:1 and 2:1 and these cocultures, as well as
the monocultures of each cell line, were maintained for 48
hours before RNA isolation.
Indirect cocultures are defined as a coculture where the
fibroblasts and cancer cells are separated by a porous
membrane that allows cell–cell communication via sol-
uble factors. For indirect cultures, fibroblasts were seeded
on inserts on Corning (Tewksbury, MA, USA) Transwell
plates with 0.4 μm-pore polycarbonate membranes; epi-
thelial cells were grown in the bottom well. Indirect cul-
tures were plated at a 1:1 ratio and maintained for 48
hours before RNA isolation.
RNA and expression microarrays
Cells were harvested by scraping in RNA lysis buffer. Total
RNA was isolated using the RNeasy mini kit (Qiagen,
Valencia, CA, USA) and RNA quantification was performed
on a ND-1000 Nanodrop spectrophotometer and RNA
quality was analyzed on an Agilent 2100 Bioanalyzer using
a RNA6000 nano chip (Agilent, Santa Clara, CA, USA).
Microarrays were performed according to the Agilent
protocol using two-color Agilent 4×44K V2 (Agilent
G4845A). We used the Agilent Quick Amp labeling kit and
protocol to synthesize Cy3-labeled reference from Strata-
gene Universal Human Reference spiked at 1:1,000 with
MCF7 RNA and 1:1,000 with ME16C RNA to increase ex-
pression of breast cancer genes. The identical protocol was
applied to total RNA from cocultured or monocultured cell
lines to label these samples with Cy5. Labeled cDNAs were
hybridized to arrays overnight and washed before scanning
on an Agilent G2505C microarray scanner.
Coculture data normalization and analysis
Data from 47 microarrays (representing monocultures, dir-
ect cocultures, and indirect cocultures from six different
cell lines) were included in this study. Microarray data are
available in the Gene Expression Omnibus [GSE43467].
Only those genes where more than 70% of microarrays
had signals in both channels greater than 10 dpi were in-
cluded. Data were Lowess normalized and missing data
were imputed using k-nearest neighbors’ imputation.
For the direct coculture analyses, we excluded genes
that did not have at least twofold deviation from the mean
in at least one sample and the method of Buess and
colleagues [14] was used to normalize cocultures toappropriate monocultures performed in the same media
and under identical conditions as described previously [5].
Briefly, the Buess method is an example of an expression
deconvolution approach applied to coculture data; this
method estimates the percent of fibroblasts and cancer
cells in each coculture, and normalizes the data for com-
position differences prior to estimating the effect of epi-
thelial–stromal interaction on gene expression. The Buess
interaction coefficient I was calculated as the ratio of ob-
served to expected gene expression and an I-matrix
representing the epithelial–stromal interaction coefficient
for each gene in each coculture was generated. The esti-
mated I value for each gene and coculture can be thought
of as an indicator of the ratio of that gene’s expression
level relative to the expected level based on the cellular
composition and the monoculture expression values.
For coculture studies, I-matrices were analyzed using
multiclass significance analysis of microarrays [15], com-
paring MCF10A cocultures with MCF10AT cocultures
with MCF10DCIS cocultures (three classes).
Microarray analysis was carried out using R version
1.14. Heatmap generation and visualization were
performed using Cluster 3.0 and Java treeview, respect-
ively. Functional and pathway analyses were carried out
using ingenuity pathway analysis (IPA, Redwood City,
CA, USA), with Benjamini–Hochberg multiple testing
correction to identify significant functions and pathways
with P <0.05. Pathways and functions with two or fewer
genes were excluded from our analysis.
Calculation of basal-like interaction score
We utilized gene sets identified in Camp and colleagues
[5] to score each coculture for the degree to which it
expressed basal-like microenvironment genes. In Camp
and colleagues’ study a 30-gene signature was identified
that predicted basal-like versus luminal interactions in
cocultures and that also distinguished basal-like versus
luminal tumors. Using I values (as described above) for
each of these 30 genes across all cocultures, we com-
puted a basal-like interaction score. Briefly, using the
method of Creighton and colleagues [16], vectors corre-
sponding to the 30 genes in the basal-like signature were
constructed, with 1 assigned to genes upregulated in
basal-like cocultures/cancers and −1 assigned to
downregulated genes. A Pearson correlation coefficient
was calculated for this standard vector versus the vector
of I values for each coculture experiment. The Pearson
correlation coefficient from this analysis is defined as the
basal-like interaction score.
Analysis of cytokine expression in conditioned media
(cytokine array)
To identify soluble mediators of basal-like microenviron-
ments in the MCF10DCIS cells, conditioned media
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coculture media conditions as described above) were ana-
lyzed according to manufacturer protocol on a RayBio
Human Cytokine Antibody Array 5 (80) (Raybiotech,
Norcross GA, USA) designed to detect 80 cytokines and
chemokines. Briefly, slides were blocked by incubation
with blocking buffer at room temperature for 30 minutes
and incubated with 100 μl conditioned media at room
temperature for 90 minutes. Slides were washed and incu-
bated with biotin-conjugated antibodies overnight at 4°C.
Finally, the slides were washed and incubated with fluores-
cent dye-conjugated streptavidin at room temperature for
2 hours. After final washing, slides were dried by centrifu-
gation at 0.2 RCF (Centrifuge 5702R; Eppendorf,
Hauppauge, NY, USA) for 3 minutes. The fluorescent sig-
nal was detected on a laser scanner (Axon, Molecular De-
vices, LLC, Sunnyvale, CA, USA) using a Cy3 (green)
channel (excitation frequency 532 nm). Data for each
cytokine were normalized to positive controls on the same
slide to estimate relative protein expression. Each mono-
culture or direct coculture was analyzed in duplicate.
Western blot
Cells were harvested from interaction cocultures and
protein was isolated and quantified as described pre-
viously [17]. Lysates were denatured by boiling with
β-mercaptoethanol, and 15 to 30 μg protein were
electrophoresed on a 4 to 20% Tris–HCl Criterion pre-
cast gel (Bio-Rad, Hercules, CA, USA) and transferred to
a Hybond-P membrane (Amersham-GE Healthcare Life
Sciences, Pittsburgh, PA, USA) by electroblotting. The
blots were probed with antibodies against the receptor
MET (#8198S; Cell Signaling, Beverly, MA, USA), HGFα
chain (sc-166724; Santa Cruz, Dallas, TX, USA) and
β-actin (#4967; Cell Signaling, Beverly, MA, USA). Blots
were washed three times with Tris-buffered saline
supplemented with 0.1% TWEEN and then were probed
with ECL anti-mouse IgG horseradish peroxidase-linked
whole antibody from sheep (Amersham-GE Healthcare,
Life Science). Blots were rewashed, and detection was by
enhanced chemiluminescence western blotting detection
system (Amersham-GE Healthcare Life Science). Relative
MET and HGF protein concentrations were quantified
using ImageJ software, with the pixel intensity of the MET
or HGF protein band divided by the pixel intensity of the
β-actin band. Fold-change expression was calculated by
dividing the coculture expression by the monoculture
expression at that same time point.
Quantitative PCR for MET and HGF
The relative quantity of HGF (Hs00300159_m1, ABI
catalogue number 4331182) and MET (Hs01565584_m1,
ABI catalogue number 4331182) mRNA was assayed by
quantitative PCR using an ABI 7900HT machine (LifeTechnologies, Carlsbad, CA, USA). mRNA was isolated
from cells using Qiagen’s RNeasy mini kit and protocols
(Qiagen, Valencia, CA, USA). Then 1 μg total RNA was
reverse transcribed into cDNA using the iScript cDNA
synthesis kit and protocol from Bio-Rad. The cDNA was
then diluted fivefold by the addition of 80 μl water. Sub-
sequently, 2 μl cDNA and 18 μl master mix 10 μl
SsoFast 2X Probes Supermix (Bio-Rad), 0.5 μl 18S-VIC
and 0.5 μl gene-specific Assay-On-Demand-FAM (ABI
Life Technologies, Grand Island, NY, USA), 7 μl water
were used in each well of the quantitative PCR 96-well
plate. Amplification conditions were as follows: one
cycle of 95°C for 1 minute, 40 cycles of 95°C for 5
seconds, and 60°C for 20 seconds.
Generation of coculture-derived HGF signature
To identify HGF-regulated genes, monocultures of
MCF10DCIS cells were grown in serum-free media and
treated with recombinant human HGF (294-HG/CF; R&D
Systems, Minneapolis, MN, USA) for 6 hours with
addition of HGF every hour at a 100 ng/ml concentration
(half-life of HGF is approximately 4 minutes). Total RNA
was isolated after 6 hours of treatment and analogous co-
cultures with fibroblasts were performed. Microarray data
from both HGF-treated and fibroblast-cocultured cell lines
were normalized to sham monocultures (monocultures in
serum-free media with no recombinant human HGF and
monocultures in regular media) by subtracting the log2(R/
G) values of the monoculture. The resulting log2(R/G) ra-
tio represents the response to coculture or treatment rela-
tive to that of sham. To identify genes that were
differentially regulated by both coculture and HGF treat-
ment, a one-class significance analysis of microarrays was
performed with all HGF-treated and cocultured arrays first
normalized to sham monocultures. Functional and path-
way analyses of the resulting gene signatures were
performed <less than 0.05 after Benjamini–Hochberg mul-
tiple testing correction.
Correlation with HGF signature in human tumors
We evaluated the behavior of our HGF signature (de-
scribed above) in 707 breast cancer samples from three
publically available datasets: NKI295 (N = 295) [18],
Naderi and colleagues (N = 135) [19], and UNC337 sam-
ples (N = 277) [20]. First, intrinsic subtype classification
was performed using the PAM50 predictor of Parker and
colleagues [21]. Next, expression of the HGF signature
was evaluated by mapping the 280-gene HGF signature to
all three datasets. A common probe set representing 109
unique genes was identified. These probes were median-
centered across samples, and then duplicate genes were
collapsed to a unique entry ID by statistical mean. Tumors
were classified as HGF-positive or HGF-negative using
methods described above and in Creighton and colleagues
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HGF signature (HGF-positive) and correlations ≤0 were
classified as HGF-negative. We then obtained a chi-square
statistic (four degrees of freedom) to test the association
between tumor subtype (basal-like, luminal A, luminal B,
Her2, normal-like) and HGF class (HGF-positive vs. HGF-
negative). All statistical analyses were performed using R
version 1.14 and Bioconductor packages.
Three-dimensional morphogenesis assay
3D cocultures were performed as described previously
[22,23]. A model system similar to that of Jedeszko and
colleagues was used; however, our RMF lines are not
engineered to overexpress HGF [24]. Briefly, a 1:3 ratio of
epithelial:RMF cells were cocultured in a 3D extracellular
scaffold composed of a 1:1 mixture of biologically derived
collagen I and Matrigel® (BD Biosciences, San Jose, CA,
USA). The final concentration of collagen I was 1 mg/ml.
One well from a 24-well plate was prepped for coculture
by coating with 500 μl Matrigel®–collagen mix. Then, 1 ml
cell suspension in Matrigel®–collagen mix was plated. Cul-
tures were maintained in a humidified, 37°C, 5% CO2 in-
cubator for 2 weeks, with media change every 2 days. To
test the role of HGF in morphogenesis of these cocultures,
a set of plates were cultured with neutralizing, anti-HGF
antibody (0.5 mg/ml, Abcam10678; Abcam, San Francisco,
CA, USA), which was added every day for 2 weeks using
previously published protocols [13].
The Matrigel®–collagen-embedded 3D structures were
fixed after 2 weeks using 4% paraformaldehyde (USB,
Cleveland, OH, USA) overnight. Fixed cultures were then
cryopreserved in 20% sucrose in 0.1 M phosphate buffer
at 4°C and washed before embedding and freezing in opti-
mal cutting temperature compound (Tissue-tek 4538;
Miles Laboratories Inc, Naperville, IL, USA). Frozen sec-
tions (6 μm) were cut for immunohistochemistry using a
Leica 1950 cryostat (Leica Biosystems, Buffalo Grove, IL,
USA). For immunostaining, slides were brought to room
temperature, hydrated and placed in citrate buffer pH 6.0
(TA135-HBH; Thermo-Fisher, Waltham, MA, USA).
Heat-induced epitope retrieval was performed using a
decloaking chamber (Biocare Medical, Concord, CA,
USA) at 95°C for 5 minutes followed by 90°C for 10 sec-
onds. Slides were cooled for 20 minutes, washed in Tris
buffer (0.05 M pH 7.6) and blocked in 10% normal goat
serum in Tris for 1 hour at room temperature. Samples
were incubated overnight at 4°C in mouse monoclonal
smooth muscle actin (M085; 1:100; Dako, Carpinteria,
CA, USA) and rabbit polyclonal cytokeratin (Z0622;
1:100; Dako). After rinsing, slides were incubated at room
temperature for 3 hours in a mixture containing goat anti-
mouse antibody (Alexafluor 568, Invitrogen A21134;
1:400) and goat anti-rabbit antibody (Alexafluor 488,
Invitrogen A11008; 1:400). Slides were washed andcoverslipped with Fluorogel II containing 4′,6-diamidino-
2-phenylindole (EM Sciences, Darmstadt, Germany). For
hematoxylin and eosin (H&E) stain, frozen sections were
stained 1 minute in acidified Harris Hematoxylin
(6765003; Thermo Scientific), rinsed in running tap water
for 4 minutes, stained for 3 minutes in alcoholic Eosin Y
(6766007; Thermo Scientific), dehydrated in 95% alcohol
for 2 minutes and for 5 minutes in absolute alcohol,
cleared in xylene for 6 minutes and coverslipped with
DPX mountant. Phase and fluorescent images were
obtained using an Olympus (Tokyo, Japan) IX-81 micro-
scope at 10× magnification.
Acinar morphology and apoptosis were assessed using
H&E slides of 3D sections. Apoptosis was present if apop-
totic bodies (small, sealed membrane vesicles) were present
[25]. Immunofluorescence staining of pan-cytokeratin was
used to score each organoid for lumen (present or absent)
and to confirm the epithelial cell identity of acinar cells.
Each structure was visualized, and classified as with lumen
if there was a clear open space within the center of the
structure or as no lumen if the lumen was filled by cells or
cellular debris. For lumen and apoptosis, 30 to 35 acinar
structures were analyzed per condition.
Lumen size and total acinar size were also measured by
a method based on optical coherence tomography (OCT).
Imaging of the 3D cultures was performed using a custom,
ultrahigh-resolution, spectral-domain OCT system as pre-
viously described in [22]. The OCT image stacks were
resampled into an isotropic pixel resolution of 1.55 μm
after correcting for the refractive index of the aqueous gels,
and displayed in a hot color map using MATLAB® (2011a,
MathWorks, Natick, MA, USA). From color-mapped
OCT images, cell clusters resembling acini were selected
based on their spherical shape. The OCT image containing
the central position of each acinus was determined by sift-
ing through the OCT image-stack to find the image with
the largest acinus size. The overall acinus area and acinus
lumen area were each characterized from these central
OCT image slices using ImageJ. The mean acini area and
mean lumen area were calculated for each gel. A total of
50 to 60 acinar structures were analyzed per condition.
Population doubling times
Cell line population doubling times (PDTs) were deter-
mined in 1:1 ratio indirect cocultures by plating 1×105 cells
in each well or insert of a six-well dish. Two dishes per cell
line were counted at 24 and 48 hours after plating. Anti-
HGF antibody (0.5 mg/ml, Abcam10678) was added every
12 hours to the cocultures. The growth of the cells during
the log phase can be modeled using the following equation:
lnA tð Þ ¼ lnA0 ¼ kt ð1Þ
where A(t) is the number of cells per plate at time t, and k
represents the first-order rate constant of cell growth, with
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mates of k were obtained for MCF10A and MCF10DCIS in
coculture with and without anti-HGF antibody. The PDT
for each cell line in each condition was calculated as:
PDT ¼ 0:693
k
ð2Þ
To compare the growth rates, k, for two cell lines, a
multiple regression model similar to that described by
Troester and colleagues [26] was employed.
Statistical analysis
Statistical analyses for experimental results were
performed using SAS 9.2 (SAS Institute, Cary, NC, USA)
(32). Analysis of variance was performed to compare
basal-like interaction scores across MCF10A, MCF10AT1
and MCF10DCIS cocultures. Two-tailed t tests were
performed to determine statistical differences between
lumen size (by OCT measurement in 3D morphogenesis
assay) of MCF10A and MCF10DCIS, with and without
anti-HGF. A chi-square analysis was performed compar-
ing the presence of apoptosis (yes/no) and lumen (yes/no)
in the 3D morphogenesis in MCF10A, MCF10DCIS and
MCF10DCIS + anti-HGF cocultures.
Results
The MCF10A series acquire basal-like microenvironment
characteristics at the DCIS stage
Each cell line in the MCF10 isogenic panel had a distinct
response to coculture with RMFs. By multiclass significanceA BMCF10A  MCF10AT1  MCF10DCIS:RMF :RMF :RMF
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Figure 1 MCF10A series progressively acquires basal-like microenviro
clustering showing interaction scores (I values) for genes that significantly c
each cell line. A gray bar adjacent to the heat map shows a cluster of gene
(B) A basal-like interaction score was developed previously by Camp and c
progression and expression of basal-like microenvironment characteristics.
the score increased with progression from A/AT1 to ductal carcinoma in sit
basal-like invasive cancer cell line SUM149. ANOVA, analysis of variance; RManalysis of microarrays, we identified approximately 700
genes as differentially expressed across these three cell lines
(Figure 1A). One set of genes was particularly upregulated
in MCF10DCIS cells, and not in MCF10A or MCF10AT
cells (gray bar in Figure 1A). This cluster of genes was ana-
lyzed by IPA (Additional file 2) and results suggest im-
mune response processes and connective tissue disorders,
such as immune cell trafficking (P = 0.021), acute phase
response signaling (P <0.001) or cell-mediated immune
response (P = 0.005). Many of these processes were also
upregulated in invasive basal-like breast cancers in direct
cocultures [5].
We utilized a gene set identified by Camp and col-
leagues [5] to directly test whether the cocultures
upregulated basal-like microenvironment characteristics.
This signature can distinguish basal-like from luminal
cocultures in vitro and can distinguish basal-like from
luminal tumors in vivo. Using this signature we calcu-
lated a score for each sample, termed the basal-like
interaction score. MCF10DCIS cells had a high basal-
like interaction score (Figure 1B), similar to that of the
invasive basal-like breast cancer cell line SUM149. In
contrast, the cocultures of premalignant MCF10AT1 and
MCF10A cells showed weakly positive basal-like inter-
action scores and the luminal MCF7 cell line showed a
negative score (Figure 1B). Pearson correlations were
also performed for the monocultures and indirect cocul-
tures of these same cell lines (Additional file 3). The cor-
relation observed in the indirect cocultures followed the
same trend as observed in direct cocultures, althoughMCF10A :RMF
MCF10AT1:RMF
MCF10DCIS:RMF
MCF7:RMF(Luminal) 
Sum149:RMF(Basal-like)
ANOVA p-value=0.0006
nment characteristics. (A) One-dimensional (genes only) hierarchical
hange due to coculture. Distinct clusters of genes are upregulated in
s that are uniquely upregulated in the MCF10DCIS:RMF cocultures.
olleagues [5]; the coculture data show a strong relationship between
Luminal cocultures had a negative basal-like interaction score, while
u (DCIS), with DCIS having interaction scores similar to those in the
F, reduction mammoplasty fibroblast.
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uated. This attenuation was expected based on dilution
and diffusion of secreted signals; in indirect cocultures,
signals from the fibroblasts are diluted in large volumes
of media, whereas in direct coculture the dependence on
diffusion kinetics and protein stability is reduced. While
neither direct nor indirect cocultures simulate the
inhibitory effects of basement membrane on cellular
signaling [27-29], direct cocultures offer important
advantages to address cell–cell signaling, particularly
when considering effectors with short half-lives. Thus,
all coculture data are from direct cocultures unless
otherwise stated.
Upregulation of secreted cytokines in MCF10DCIS
fibroblast cocultures
Having established that basal-like microenvironments
are induced by soluble factors, we sought to identify the
secreted mediators. Eighty cytokines and chemokines
were measured in the conditioned media of the direct
cocultures. A striking increase in the number of cyto-
kines expressed occurred in the MCF10DCIS cocultures,
with a total of 62 cytokines upregulated by more than
1.5-fold. In contrast, MCF10A and MCF10AT cocultures
each upregulated only a small number of cytokines
(Table 1; a full list of cytokines and their fold-change
relative to monoculture is provided in Additional file 4).
The most highly upregulated cytokine in DCIS cocul-
tures was HGF, which increased monotonically from
MCF10A to MCF10AT1 to MCF10DCIS and was
upregulated more than 80-fold in MCF10DCIS and 70-
fold in MCF10AT1 direct cocultures (Figure 2A).
When HGF secretion is measured in the conditioned
media from cocultures, the source of the HGF is not dis-
cernible. Therefore, to identify which component of the
system is producing the HGF, intracellular HGF RNA and
protein levels were measured in each cell line after 48
hours of coculture. Additional file 5 shows that HGF is ex-
clusively being produced by the fibroblasts. The epithelial
cells had no detectable levels of transcript or protein in
the monoculture; however, in coculture some HGF pro-
tein was observed in the epithelial cells, presumably due
to internalization of the receptor–ligand complex. HGFTable 1 Number of cytokines expressed in the cocultures
of the MCF10A series
Cytokine fold-change
1.5 to 3 3 to 10 >10 Total number
MCF10A:RMF - 1 - 1
MCF10AT1:RMF 5 2 1 8
MCF10DCIS:RMF 50 11 1 62
RMF reduction mammoplasty fibroblast.secretion and activation is part of a complex cascade that
regulates the actions of HGF. Consistent with previously
published results suggesting that activity of HGF is regu-
lated pericellularly on the protein level by hepatocyte
growth factor activator inhibitor type 1 (HAI-1) [30], we
found HAI-1 differentially expressed in our heat map
from Figure 1A. HAI-1 inhibits HGF activator, thereby
inhibiting the activation and subsequent activity of HGF.
HAI-1 was more highly expressed in MCF10A cocultures,
and is associated with lower HGF secreted protein by
cytokine array analysis.
HGF is the major ligand for the MET tyrosine kinase
receptor and is also a negative regulator of MET tran-
scription [31]. To evaluate whether MET is present in
these cell lines, and whether MET levels are differen-
tially regulated in coculture conditions, we assayed ex-
pression of this receptor in the MCF10 series, alone and
in coculture over the course of 48 hours. Both at the
RNA (Figure 2B) and the protein level (Figure 2C), we
observed that contact with fibroblasts (6 hours) induced
the MCF10DCIS cells to markedly upregulate MET
RNA. Peak RNA induction at 6 hours is followed by
peak protein expression at 12 hours. This effect was not
observed (in MCF10A) or markedly diminished (in
MCF10AT1) in the other two cell lines of the series. The
interaction of MCF10DCIS cells with RMF in coculture
thus stimulates an increase in HGF secretion and a con-
comitant increase in epithelial HGF receptor, MET,
expression.
An in vitro-generated HGF gene signature correlates with
basal-like tumors
Our coculture results established a fold-change increase
in HGF signaling in premalignant, basal-like microenvi-
ronments; however, if these changes are essential for
basal-like breast carcinogenesis, then they should also be
present in invasive basal-like breast cancers. To assess
this hypothesis, we generated an in vitro HGF signature.
We identified gene expression changes that occurred in
both MCF10DCIS monocultures treated with recombin-
ant human HGF and cocultures of MCF10DCIS with
RMFs. These HGF-regulated genes are most likely to be
effecting the action of HGF on MET in coculture. IPA
analysis of the HGF signature suggested sonic hedgehog
signaling (P = 0.007), basal cell carcinoma signaling
(P = 0.017), and tight junction signaling (P = 0.020)
among other signaling pathways were upregulated by
HGF signaling in cocultures.
Using this signature we scored 707 invasive tumors
from three independent datasets as having a high or low
correlation with this HGF signature. Figure 3A shows
that 86% of the aggressive basal-like tumors in these
datasets are positively correlated with the HGF signa-
ture, whereas only 23.6% of the luminal A tumors
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Figure 2 MCF10A series cocultures present differentially secreted cytokines and MET receptor status. (A) A variety of cytokines are
overexpressed in the direct cocultures of all three cell lines. The number of cytokines overexpressed increases with progression. The cytokine
most strongly overexpressed was hepatocyte growth factor (HGF). (B) MET RNA fold-change expression relative to the corresponding cell line in
monoculture over a 48-hour period. We observe a sharp increase of transcript in the MCF10DCIS cells when in coculture after 6 hours. (C) MET
protein fold-change expression relative to the corresponding cell line in monoculture over a 48-hour period. The protein increase is delayed 6
hours when compared with RNA expression due to the delay in translation. FGF, fibroblast growth factor; GCP, granulocyte chemotactic peptide;
GCSF, granulocyte colony-stimulating factor; MCP, monocyte chemotactic peptide; MIG, monokine induced by interferon-gamma; RANTES,
regulated on activation, normal T-cell expressed and secreted; RMF, reduction mammoplasty fibroblast.
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http://breast-cancer-research.com/content/15/5/R82present a positive association. Additionally, 40% of
Her2-like tumors and 36% of luminal B tumors, both
of which are more aggressive than luminal A tumors,
were positively associated with the HGF signature
(P <2.2×10–16). Furthermore, among basal-like patients
that are positive for the HGF signature, patients had worse
overall survival (Figure 3C). These results emphasize the
importance of HGF signaling in aggressive breast cancer.
While our coculture results show that HGF signaling is
already present at the DCIS stage, the importance of this
pathway in survival illustrates that the dysregulation of the
HGF pathway persists in invasive basal-like tumors and
contributes to their progression.
Blocking of HGF inhibits three-dimensional
morphogenesis
Our previous studies of basal-like versus luminal cocul-
tures indicated that hepatic fibrosis signaling was
upregulated in basal-like cocultures [5]. In light of our
current data illustrating that (1) MCF10DCIS:RMF cocul-
tures have high basal-like interaction scores, (2) that HGF
was secreted/active in MCF10DCIS cocultures, and (3)
that HGF signaling is over-represented among invasive
basal-like tumors and is prognostic of overall survival, we
used HGF-targeted antibodies to study the role of HGF inthe basal-like interaction score and functional morpho-
genic coculture assays. First, MCF10DCIS:RMF cocultures
were incubated for 36 hours to allow for epithelial–stromal
interactions to occur, and for the last 12 hours anti-
HGF antibody was added every 2 hours. In Figure 4A we
observe a decrease in the basal-like interaction score due
to anti-HGF treatment. While there is variation (due to
random or other unexplained causes) in the time-course
data such that 4, 8 or 12 hours after exposure have basal-
like interaction scores ranging from negative to slightly
positive, it is clear that at all three time points the score is
dramatically reduced.
Morphogenic assays have been shown to track normal,
physiological acinar development as well as pathological
malignant potential of epithelial cells [32]. The Brugge and
Bissell laboratories have characterized the development
of 3D structures over time in MCF10A cells, identifying
important morphogenic mechanisms [33-35]. Namely,
morphogenesis represents a balance between a variety of
physiologic and pathologically-relevant processes including
cell proliferation, apoptosis, and cellular migration [33]. We
applied morphogenesis assays to develop an integrated pic-
ture of how key cellular phenotypes change with and with-
out HGF signaling. Briefly, the expected development of
MCF10A cells in 3D dictates that by 6 to 8 days they have
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Figure 3 Hepatocyte growth factor signaling is present in vivo in basal-like tumors. An in vitro generated signature that captures
hepatocyte growth factor (HGF) signaling is highly correlated with invasive basal-like tumors. (A) Number of tumors that are positively and
negatively correlated with the HGF signature by subtype. (B) Creighton correlation of each basal-like and luminal tumor with the HGF signature;
the degree of positivity among basal-like tumors is higher when compared with the luminal tumors (scale bar). (C) Kaplan–Meier survival curves
for overall survival among patients that were positive or negative for the HGF signature. Patients with basal-like tumors with positive HGF
signatures had worse overall survival over a period of 14 years.
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http://breast-cancer-research.com/content/15/5/R82reached their final size and will then start acquiring a
lumen through apoptosis of the centrally located cells
[36-38]. Using this as a metric, we performed 3D cocultures
of MCF10A and MCF10DCIS with RMFs in a Matrigel®–
collagen mix for 2 weeks. Cells were treated in the presence
or absence of an anti-HGF antibody and the resulting
acinar structures were analyzed using two techniques:
longitudinal OCT imaging at two time points (1 week and
2 weeks), and traditional H&E and immunofluorescence
staining at 2 weeks.To track the morphogenesis of these cell lines over
time, we used OCT because we have previously found
that OCT imaging allows for longitudinal 3D in vitro
imaging without disruption of the acinar structures [22].
In addition, with these images we can estimate the size
of the acinar structures and their lumens. After counting
50 structures per condition, we observed no overall dif-
ference in the size of MCF10DCIS cocultures with and
without anti-HGF antibody treatment. However, blocking
HGF resulted in a statistically significant decrease in
Figure 4 Blocking hepatocyte growth factor signaling reverses basal-like microenvironments and slows morphogenesis in three-
dimensional coculture. (A) Basal-like interaction score of MCF10DCIS:RMF direct cocultures when treated with anti-hepatocyte growth factor
(anti-HGF) antibody (as described in Materials and methods), despite the variability basal-like score being reversed from positive association to
negative association. (B) Morphogenesis represents a balance between cell proliferation, apoptosis, and cellular migration. Morphogenesis assays
track these processes in vitro. Bar graph shows the quantification of structures with and without lumens at 2 weeks in coculture. When HGF
signaling is blocked in the ductal carcinoma in situ (DCIS) cocultures, the morphogenesis process is slowed down, causing these acinar structures
to display an intermediate phenotype between the MCF10DCIS and the MCF10A cocultures. (C) Apoptosis was lowest for DCIS at 2 weeks, these
cocultures had already undergone cavitation at that time point. Treatment with anti-HGF increases the apoptosis levels at this time-point because
of delayed the cavitation process. (D) Representative hematoxylin and eosin images of cross-sections of the 3D structures and with apoptotic
bodies. NT, not treated with anti HGF; RMF, reduction mammoplasty fibroblast.
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http://breast-cancer-research.com/content/15/5/R82lumen size (P = 0.017, Figure 4B). The MCF10DCIS
cocultures treated with the anti-HGF antibody bore
a greater resemblance to the nonmalignant MCF10A
(Additional file 6). As shown in Figure 4B, the number of
structures without a lumen is high in MCF10A cocultures,
and similar in the MCF10DCIS cocultures treated with anti-
HGF, whereas the untreated MCF10DCIS cocultures have
progressed to form a lumen (Additional file 7; P = 0.0007).
These differences cannot be attributable to differences in
proliferation rates of the cell lines, because the PDTs
(in two-dimensional indirect cocultures) are very similar;
PDTs of MCF10A and MCF10DCIS in coculture with RMF
are 21.3 and 21.5 hours, respectively. When HGF signaling
is blocked, these doubling times are 21.6 and 21.0 hours,
respectively. The morphogenesis changes thus occur in the
absence of statistically significant changes in proliferation
(MCF10A P = 0.52 and MCF10DCIS P = 0.9).Finally, H&E stains were used to measure apoptosis.
By counting the presence of apoptotic bodies in the
lumens, structures were classified as having apoptotic
bodies or not [25]. Since apoptosis is the mechanism by
which the lumens are formed [36-38], we would expect
that in cells where lumen formation is not complete
(MCF10A), the levels of apoptosis would be higher at a
given time point. Figure 4C shows that, as expected,
apoptosis was greater in the cocultures of MCF10A
compared with MCF10DCIS cocultures and that treat-
ment with anti-HGF antibody restores MCF10 apoptosis
levels to those more similar to MCF10A (Additional
file 8; P = 0.0450053). Taking these results collectively,
treatment with anti-HGF reverts the MCF10DCIS cells
to morphogenic phenotypes that resemble the less ma-
lignant cells (MCF10A), thereby blocking a microenvir-
onment-mediated increase in malignant potential.
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Breast cancer progression requires that epithelial cells
acquire capabilities that enhance their growth and sur-
vival. While biological models of cancer have tradition-
ally emphasized cell-autonomous characteristics, it is
clear that changes in the microenvironment are also ne-
cessary [8]. Castro and colleagues demonstrated that
the stroma of DCIS lesions already possess alterations
found in full invasive tumors [39], and Ma and col-
leagues and Allinen and colleagues demonstrated that
genomic changes occur in many cell populations of
the microenvironment [10,11]. These models explicitly
hypothesize that epithelial cells must undergo an evolu-
tionary adaptation to their microenvironments [1,2,40].
Other models propose that the microenvironment is the
driving force of the benign lesion evolution into full in-
vasive tumors; Gatenby and Gillies even speculate that
the origin of cancer may lie not in mutations within epi-
thelial cells, but within acquired or somatic mutation
changes in the mesenchymal cells that control tissue
structure [41]. While our data do not support these lat-
ter models, our data do suggest that progression is not
isolated to a single compartment (the epithelium), but
rather reflective of epithelium–stroma coevolution. Het-
erotypic interactions between epithelium and stroma
foster this coevolution by selecting for complementary
phenotypes in stroma and epithelium.
Evidence of progressive complementarity between
stroma and epithelium is critical to documenting coevo-
lution. For example, considering transition from pre-
invasive to invasive tumors, Hu and colleagues recently
demonstrated that NF-κB and cyclooxygenase-2 signal-
ing contributes to epithelial–stromal-mediated invasive
potential [42]. In the current study we document coevo-
lution in the earlier transition between benign and pre-
invasive lesions. A striking upregulation of HGF was
evident early in progression (at the atypical hyperplasia
stage), but was not sufficient to induce the characteristic
basal-like stromal-interaction phenotype. MET must
also be expressed, and at the DCIS stage MET was
upregulated with drastic consequences on the behavior
of the epithelial cells: MCF10DCIS cells expressed high
basal-like interaction scores and an associated ability to
progress in morphogenesis assays. Similarly increased
malignant potential has been observed in xenograft
models with MCF10DCIS, which also preserve stromal
interactions [43,44]. The importance of the HGF path-
way was further documented in our system by blocking
HGF signaling with an antibody, resulting in reversal of
expression and morphologic phenotypes. In fact, this lat-
ter experimental work underscores an advantage of our
in vitro coculture system: in studying cancer evolution
using this cell line panel, pathways can be manipulated
and direct causal effects can be examined. We were alsoable to separately assay both epithelial and stromal char-
acteristics and show complementary changes. Epithelial
cells upregulate the MET receptor only at the DCIS
stage, despite HGF expression by all cocultured fibro-
blasts. While other studies have reported HGF expres-
sion by breast epithelial cells [45,46], these studies utilize
different cell line models of progression and we did not
observe a similar autocrine pathway of HGF–MET inter-
action in our studies. The previous studies focused on
cell line models of metastatic progression, so perhaps
our focus on pre-invasive stages of disease accounts for
differences between findings. It is interesting to consider
that by later stages of progression, this pathway may de-
velop autocrine capability. By studying the interactions
and the relative contributions of each component at dif-
ferent stages of progression, we can better understand
how stroma and epithelium are coevolving.
Our results emphasize that HGF/MET signaling is im-
portant in basal-like breast cancer progression from
early in the disease, but HGF has long been studied in
invasive cancer biology and in normal development
[47,48]. Previous studies have linked HGF/MET signal-
ing with poor outcome in invasive breast cancers [49].
Several recent publications have demonstrated the im-
portance of HGF/MET signaling and the microenviron-
ment in melanoma treatment resistance [50,51]. Our
data, using a novel HGF signature and three independ-
ent tumor datasets, indicate that HGF/MET signaling is
highly correlated with basal-like breast cancer subtype
and worse overall survival in patients. Mouse models
with overexpression of MET induce basal-like tumors
with signatures of WNT and epithelial to mesenchymal
transition [52], suggesting that this pathway’s importance
in tumor biology is conserved across species. In normal
tissue, HGF is produced by stromal fibroblasts and acts
as a mitogen, motogen and morphogen on MET-
expressing epithelial cells [53]. MET is a tyrosine kinase
receptor that, when activated by its ligand (HGF), auto-
phosphorylates and initiates an intracellular signaling
cascade that involves many targets. In the developing
mammary duct, deletion of epithelial MET inhibits
ductal branching [54]; and in adult glands, HGF is crit-
ical for tubulogenesis [55]. The HGF/MET pathway is
thus an essential player in normal development and
wound healing [56,57]. Given the high expression of
wound response genes in the tissue adjacent to cancer
[58] and the important role of HGF in normal ductal
morphogenesis and invasive breast cancer, a better un-
derstanding of HGF/MET in progression of basal-like
breast cancers is important.
Future work should focus on studying how molecules
that block MET signaling affect stromal–epithelial inter-
actions and should study HGF/MET in tissue from pre-
invasive basal-like lesions. One case series reported by
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MET signaling in earlier lesions by immunohistochemis-
try studies of HGF and MET in DCIS [59]. Their study
concluded that an imbalance in MET expression be-
tween the tumor and the surrounding normal tissue is
associated with aggressive DCIS phenotypes. However,
uncertainty remains about how the imbalance can best
be characterized in human tissue. Studying cell–cell
communication is difficult in tissue, so the availability of
complementary in vitro models is helpful. While these
models rely on single cell lines and cannot represent the
diversity of stromal phenotypes observed in humans,
these coculture models advance our understanding of
the reciprocal molecular changes in the pre-invasive
stages of breast cancer and can guide research on tissue.
Conclusion
Heterotypic interactions are crucial for disease progres-
sion; both compartments, the stroma and the epithe-
lium, must coevolve to produce a successful tumor.
Understanding the reciprocal epithelial and stromal
changes that occur in early lesions will help to identify
strategies to treat patients and/or prevent invasive breast
cancers. HGF/MET signaling is a strong candidate path-
way for treating premalignant basal-like lesions and the
application of MET inhibitors should be considered in
preclinical models to advance this plausible strategy.
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Additional files
Additional file 1: Figure S1. Primary fibroblasts have temporal and
intra-individual instability. mRNA quantification of HGF across a panel of
14 primary fibroblasts lines and the RMF cell line in coculture with the
MCF10A progression series. Primary fibroblasts were isolated from five
patients both from the cancer-adjacent tissue (CNAF: cancer-normal
associated fibroblasts) and the tumor itself (CAF: cancer-associated-
fibroblasts). HGF levels vary at the transcriptional level between patients
and between passages. *Samples had no detectable levels of transcript
by quantitative PCR.
Additional file 2: Table S1. IPA pathway analysis and biological
function analysis of genes upregulated in MCF10DCIS:RMF direct
cocultures.
Additional file 3: Figure S2. MCF10A series progressively acquires
basal-like microenvironment characteristics also when in interaction
cocultures. Basal-like interaction score of monocultures (M), indirect
cocultures (I) and direct cocultures (D). Indirect cocultures maintain the
trends of the basal-like interaction score present in the direct
cocultures (from Figure 1B).
Additional file 4: Table S2. List of cytokines detected on the antibody
based array with the values for each coculture.
Additional file 5: Figure S3. HGF is produced by the stromal component
of the cocultures, the RMFs. (A) RNA levels of HGF (ΔCT values relative to the
18s gene) in the monocultures of the MCF10A series and the RMFs, as wellas these cell lines in coculture. The epithelial cells had no detectable levels of
HGF transcript (*) even in coculture with RMFs; only RMFs had high levels of
the transcript. (B) Protein levels of HGF, again of cells in monoculture or
coculture. Epithelial cells in monoculture had no detectable levels of HGF (#);
however in coculture they appear to have some HGF protein, and we argue
this is due to the internalization of the receptor–ligand complex. RMFs had
high levels of HGF expression both in monoculture and in coculture. Both
graphs demonstrate the same trend, the stromal cells are responsible for HGF
secretion in this coculture system.
Additional file 6: Figure S4. OCT measurements of the acini structures.
(A) Representative fluorescent pictures of acinar structures stained with
pan-cytokeratin (green) and 4′,6-diamidino-2-phenylindole (DAPI;
nucleus), the left picture shows a structure without a lumen and the
right picture represent a structure with a very well-defined lumen.
(B) Graphs representing the evolution of the overall size (area) of the
acini and the size of the lumen (lumen). Anti-HGF treatment does not
affect the overall size of the 3D structures; however, it has a big
influence on the area of the lumen (*P = 0.017). Acini with anti-HGF
treatment present smaller lumens resembling the more benign cell
line MCF10A. Diagram adapted from [37], which shows the
progression overtime of the different 3D cocultures that were
performed. MCF10DCIS:RMF progress much faster through the
morphogenesis assay than the MCF10A:RMF; MCF10DCIS:RMF
depleted of HGF signaling present a phenotype similar to the less
aggressive MCF10A.
Additional file 7: Table S3. HGF signature: 280 genes that were
upregulated (red) or downregulated (green) in the generated HGF
signature.
Additional file 8: Table S4. Chi-square analysis of 3D quantification of
the morphological assay. Lumen and apoptosis quantification.
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